ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Biotechnology

Healthcare
$10.90 +1.40%

+$0.44 today

Market cap
$563.78M
Beta
1.42
P/E (TTM)
-9.8
EPS (TTM)
-$3.22
52W Low $16.10High $33.62

Volume 2.70M

Average 0.50M

AVBP Purchases of Investments

Cash used to buy marketable securities and other investments.

ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments growth accelerates

Q1 FY2026 purchases of investments of $64.38M (cash outflow) rose 555.8% year over year, ahead of the +60.6% change in trailing-twelve-month purchases of investments. Sequentially, it fell 57.4% from the prior quarter.

Context

  • Purchases of investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +555.8% holds above the trailing-twelve-month pace of +60.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$64.38M-57.4% QoQ
Last fiscal yearDec 2025
-$272.93M+40.6% YoY
LTMMar 2026
-$327.5M+60.6% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+555.8%——
1 year+40.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(272.93M) USD
Year-over-year change
-40.6%

Purchases of Investments vs competitors

How AVBP compares with its peers on the latest reported figures

  • AVBP's LTM Mar 2026 purchases of investments of $327.5M is the 5th largest of the 11 companies compared; the peer median is $198.58M.
  • Its year-over-year change of +60.6% is the 6th highest of 11, against a peer median of +69.2%.
AVBP Competitors Peer median
Purchases of Investments for AVBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ERASErasca, Inc.LTM Sep 2026$820.26M +366.4%+4.0%—
EXELExelixis, Inc.LTM Jul 2026$686.99M -29.1%-24.2%28.2%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$545.29M -33.6%+33.4%242.1%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$413.13M +104.3%+18.9%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$327.5M +60.6%——
TYRATyra Biosciences, Inc.LTM Mar 2026$256.59M -0.8%——
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$140.56M +49.4%+39.7%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$120.5M +89.0%+181.7%53.0%
NUVBNuvation Bio Inc.LTM Jun 2026$7.46M -97.1%-12.0%4.4%
ZLABZai Lab LimitedLTM Jun 2026$0 +100.0%-66.3%0.0%
HCMHUTCHMED (China) LimitedLTM Jun 2025$0 +100.0%+31.8%0.0%
Peer median (excluding AVBP) $198.58M+69.2%+18.9%16.3%

Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(51.61M)(36.91M)(69.33M)(80.49M)(166.31M)
Depreciation & Amortization0000(3.03M)
Deferred Income Tax00000
Stock-Based Compensation66.67K424K895K3.21M12.52M
Change in Working Capital(3.94M)(7.15M)12.6M7.07M(3.77M)
Accounts Receivables00000
Inventory00000
Accounts Payables293K2.8M1.38M(751K)2.14M
Other Working Capital(4.23M)(9.95M)11.22M7.82M(5.92M)
Other Non-Cash Items42.96M0000
Operating Cash Flow(12.59M)(43.63M)(55.84M)(70.21M)(160.59M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00(25M)(194.16M)(272.93M)
Sales of Investments0025M1.7M201.71M
Other Investing Activities(40M)0000
Investing Cash Flow(40M)00(192.47M)(71.23M)
Debt Repayment00000
Common Stock Issued89.87M2K354K185.95M202.63M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities015K(2.06M)631K(70K)
Financing Cash Flow89.87M169.72M42.86M186.58M203.06M
Effect of Forex Changes00000
Net Change in Cash37.28M126.09M(12.98M)(76.1M)(28.75M)
Free Cash Flow(12.59M)(43.63M)(55.84M)(70.21M)(160.59M)

ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Intrinsic Alpha fair value

Locked

Current Price

$10.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.